Myasthenia gravis (MG) is a rare autoimmune disease that can impact vision, speech, mobility, and breathing, but treatments ...

What were the most significant improvements seen in the Myasthenia Gravis-Activities of Daily Living and Quantitative ...

Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader VYVGART Use Across MG And CIDP. <li /> ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular ...

CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases.

A growing number of new treatments for myasthenia gravis (MG) are changing how doctors manage the disease and offering new options for people whose symptoms aren’t fully controlled. In recent years, ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. The fatigue associated with MG is often described as fatigable weakness, meaning ...

Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. An mRNA‑based CAR T therapy called Descartes‑08 is giving many people with myasthenia gravis ...

Myasthenia gravis (MG) is an often invisible condition that can have a significant impact on daily life. Three people living with MG describe their unique experiences and offer advice for others who ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help people with generalized myasthenia gravis, a disease where the body ...